The U.S. Food and Drug Administration has approved the ResQCPR System to perform cardiopulmonary resuscitation (CPR) on cardiac arrests patients. The CPR system is from startup Advanced Circulatory Systems, which was acquired for an undisclosed amount by Zoll Medical in January.
The share price of China's Mindray Medical rose 16% last week on the New York Stock Exchange amid rumors that it will be taken over by private equity firms, including the country's state-owned investment company.
As AbbVie's $21 billion deal to buy Pharmacyclics shows, drugmakers aren't scared to shell out for cancer drugs--and they're not worried about pricing pressure holding their purchases back. Could PD-1 pioneer Bristol-Myers Squibb be next?
Alkermes is selling off a manufacturing plant in a deal worth up to $170 million, cashing out of some royalty streams to better invest in its late-stage pipeline of new therapies.
Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.
It's just Friday, but the Monday morning quarterbacking on AbbVie's Pharmacyclics buy is in full swing. Did AbbVie overpay at $21 billion? Should it have let Johnson & Johnson take the prize instead? Does the rich deal for Pharmacyclics spell trouble for pharmas looking to make biotech buys? And really, did AbbVie overpay?
Mallinckrodt will slap down $2.3 billion to buy Ikaria, a privately held drug company, and its respiratory med for babies in neonatal ICUs. The deal will help Mallinckrodt grow its hospital drugs business, with a $150 million boost to revenue this year.
Pharma company Mallinckrodt will scoop up Ikaria, the maker of a drug-device combination product to help newborns suffering from respiratory failure breathe better.
While the industry was largely focused on the jaw-dropping sum being paid for Pharmacyclics today, Arrowhead Research has come in to buy up Novartis' cast-off RNAi business for the bargain rate of $10 million in cash and $25 million in stock.
After nixing his company's $55 billion deal for Shire last fall, AbbVie CEO Richard Gonzalez reminded investors that his company still had the "wherewithal to be active on the M&A front." Now, he's putting his money where his mouth is--and shelling out $21 billion for cancer drugmaker Pharmacyclics.